- Home
- RNAZ vs KAVL Comparison
RNAZ vs KAVL Comparison
Compare RNAZ & KAVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNAZ
- KAVL
- Stock Information
- Founded
- RNAZ 2016
- KAVL 1998
- Country
- RNAZ United States
- KAVL United States
- Employees
- RNAZ N/A
- KAVL N/A
- Industry
- RNAZ Biotechnology: Pharmaceutical Preparations
- KAVL Medicinal Chemicals and Botanical Products
- Sector
- RNAZ Health Care
- KAVL Health Care
- Exchange
- RNAZ Nasdaq
- KAVL Nasdaq
- Market Cap
- RNAZ 7.2M
- KAVL 7.9M
- IPO Year
- RNAZ 2021
- KAVL N/A
- Fundamental
- Price
- RNAZ $0.53
- KAVL $0.56
- Analyst Decision
- RNAZ Strong Buy
- KAVL
- Analyst Count
- RNAZ 1
- KAVL 0
- Target Price
- RNAZ $20.00
- KAVL N/A
- AVG Volume (30 Days)
- RNAZ 16.6M
- KAVL 93.7K
- Earning Date
- RNAZ 05-14-2025
- KAVL 04-15-2025
- Dividend Yield
- RNAZ N/A
- KAVL N/A
- EPS Growth
- RNAZ N/A
- KAVL N/A
- EPS
- RNAZ N/A
- KAVL N/A
- Revenue
- RNAZ N/A
- KAVL $3,877,695.00
- Revenue This Year
- RNAZ $180.81
- KAVL N/A
- Revenue Next Year
- RNAZ N/A
- KAVL N/A
- P/E Ratio
- RNAZ N/A
- KAVL N/A
- Revenue Growth
- RNAZ N/A
- KAVL N/A
- 52 Week Low
- RNAZ $0.43
- KAVL $0.52
- 52 Week High
- RNAZ $66.33
- KAVL $9.69
- Technical
- Relative Strength Index (RSI)
- RNAZ 28.52
- KAVL 33.73
- Support Level
- RNAZ $0.43
- KAVL $0.52
- Resistance Level
- RNAZ $0.61
- KAVL $0.60
- Average True Range (ATR)
- RNAZ 0.17
- KAVL 0.05
- MACD
- RNAZ 0.21
- KAVL 0.02
- Stochastic Oscillator
- RNAZ 8.24
- KAVL 27.34
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.
About KAVL Kaival Brands Innovations Group Inc.
Kaival Brands Innovations Group Inc is focused on growing and incubating innovative and profitable products. The company is engaged in the sale, marketing and distribution of electronic nicotine delivery system (ENDS) products and related components. Its primary product includes Bidi Stick. The BIDI Stick comes in a variety of flavor options for adult cigarette smokers.